<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984760</url>
  </required_header>
  <id_info>
    <org_study_id>WG-PBB00302</org_study_id>
    <nct_id>NCT03984760</nct_id>
  </id_info>
  <brief_title>Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis</brief_title>
  <official_title>A Multicenter, Randomized, Open‐Label, Active‐Controlled, Parallel Study to Assess the Efficacy and Safety of Ferric Citrate Capsules for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panion &amp; BF Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Weigao Panion Pharmaceutical Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Panion &amp; BF Biotech Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of ferric citrate capsules for the treatment of
      hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open‐label, active‐controlled, parallel, phase III study
      which aims to assess the efficacy and safety of ferric citrate capsules for the treatment of
      hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis. This study
      is consisting of a Screening/Washout period (14 days) and a Treatment/Observation period (12
      weeks). During the Treatment period, the subjects will be randomly assigned to the ferric
      citrate capsule group (study group) or sevelamer carbonate tablet group (control group) in
      the ratio of 1:1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">October 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in serum phosphorus levels</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The change in serum phosphorus levels at the end of treatment (Visit 10 or ET) as compared to baseline (before the first dose).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum phosphorus levels</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Serum phosphorus levels at the end of treatment;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects whose serum phosphorus levels reached the target range.</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The proportion of subjects whose serum phosphorus levels reached the target range (3.5 to 5.5 mg/dL, 1.13 to 1.78 mmol/L) at the end of the treatment;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The response rate of serum phosphorus</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The response rate of serum phosphorus at the end of treatment (defined as reduction of the serum phosphorus level exceeds 25% as compared to baseline);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in serum calcium (corrected) levels</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The change in serum calcium (corrected) levels at the end of treatment as compared to baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the [Ca] × [P] product relative</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The change in the [Ca] × [P] product relative at the end of treatment as compared to baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the level of intact‐PTH levels</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The change in the level of intact‐PTH levels at the end of treatment as compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>Ferric Citrate Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric Citrate Capsule, product specification: 500 mg/cap, manufactured by Panion &amp; BF Biotech Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer Carbonate Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevelamer carbonate tablet group, product specification: 800 mg/tablet, manufactured by Genzyme Ireland Limited</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Citrate</intervention_name>
    <description>Take the capsules with meals or immediately after meals.</description>
    <arm_group_label>Ferric Citrate Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Carbonate</intervention_name>
    <description>Take the tablets with meals.</description>
    <arm_group_label>Sevelamer Carbonate Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to give written informed consent.;

          2. Between the age of 18 and 75 years (including the boundary value);

          3. Patients who maintain the hemodialysis schedule as 3 times a week and the dialysis
             schedule should remain unchanged during the study period;

          4. At Screening, patients who have received phosphate binder for at least 4 weeks and
             have a serum phosphorus level between 2.5 and 8.0 mg/dL (0.81 to 2.58 mmol/L)
             (excluding the boundary value) after treatment;

          5. Patients with a serum phosphorus level between 5.5 and 10.0 mg/dL (1.78 to 3.23
             mmol/L) (excluding the boundary value) after washout.

        Exclusion Criteria:

          1. Patients with severe gastrointestinal diseases (such as acute peptic ulcer, chronic
             ulcerative colitis, regional enteritis, ileus) or patients with dysphagia;

          2. Patients with a history of gastrectomy or enterectomy (excluding endoscopic excision
             or caecectomy) or patients who had undergone gastrointestinal surgery within 3 months
             prior to Screening;

          3. Patients with severe constipation (times of bowel movement≤ 1 time/week), chronic
             diarrhea (times of bowel movement≥ 4 times/day), severe gastrointestinal motility
             disorder;

          4. Patients with hemochromatosis or patients receiving treatment for iron overload, or
             patients with a serum ferritin level &gt;800 ng/mL or TSAT &gt;50% at Screening;

          5. Patients with a serum calcium level (corrected) &lt;8.0 mg/dL (2.0 mmol/L) or &gt;11.0 mg/dL
             (2.75 mmol/L) after washout;

          6. Patients with intact‐PTH&gt;800pg/mL at Screening, or patients undergone parathyroid
             surgery within 6 months prior to Screening or requiring parathyroid surgery;

          7. Patients who received blood transfusions for treating anemia within 3 months prior to
             Screening;

          8. Patients who require phosphorus‐binding agents containing aluminum, magnesium, calcium
             and lanthanum in addition to the study drug or patients who require an antacid with a
             phosphorus binding effect during the study period;

          9. Patients who require citrate preparation as an anticoagulant during hemodialysis
             treatment during the study period;

         10. Patients with impaired liver function (hepatic dysfunction or serum total bilirubin,
             aspartate aminotransferase or alanine aminotransferase ≥ 2 times the upper limit of
             normal) or patients with cirrhosis;

         11. Patients with cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.)
             or cardiovascular disease (congestive heart failure of Class III or severer in NYHA
             classification, acute myocardial infarction, unstable angina, etc.) requiring
             hospitalization within 6 months prior to Screening;

         12. Patients who are known to be intolerant to sevelamer carbonate tablet;

         13. Patients with a history of allergies to iron preparations or those who are intolerant
             to iron preparations;

         14. Patients who are scheduled to have a kidney transplant during the study period;

         15. Patients with a current or past history of malignancy within 5 years prior to
             Screening;

         16. Women who are pregnant or lactating, or patients who are unable to take effective
             contraception from screening to 6 months after discontinuation (including male
             subjects and their female spouses);

         17. Patients who had participated in other clinical studies and other received
             investigational drug product within 1 month or 5 half‐lives of the drug product
             (whichever is longer) prior to Screening;

         18. Patients who are not suitable for participating in the trial according to the
             investigator's judgment;

         19. Patients who are unwilling or unable to follow the protocol process.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangmei Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>The General Hospital of the People's Liberation Army (PLAGH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shandong Weigao Panion Pharmaceutical Co. Ltd.</last_name>
    <phone>+86 13863036612</phone>
    <email>lina-xia@weigaogroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuli Sun</last_name>
    </contact>
    <investigator>
      <last_name>Xiuli Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The General Hospital of the People's Liberation Army (PLAGH)</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangmei Chen</last_name>
    </contact>
    <investigator>
      <last_name>Xiangmei Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Luo</last_name>
    </contact>
    <investigator>
      <last_name>Ping Luo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daping Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yani He</last_name>
    </contact>
    <investigator>
      <last_name>Yani He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongli Lin</last_name>
    </contact>
    <investigator>
      <last_name>Hongli Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuehong Yan</last_name>
    </contact>
    <investigator>
      <last_name>Yuehong Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital/School Of Clinical Medicine of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Lv</last_name>
    </contact>
    <investigator>
      <last_name>Lu Lv</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiujiang University Affiliated Hospital</name>
      <address>
        <city>Jiujiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinlu Gao</last_name>
    </contact>
    <investigator>
      <last_name>Xinlu Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meihekou Central Hospital</name>
      <address>
        <city>Meihekou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Guan</last_name>
    </contact>
    <investigator>
      <last_name>Yan Guan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Zhong</last_name>
    </contact>
    <investigator>
      <last_name>Aimin Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Wang</last_name>
    </contact>
    <investigator>
      <last_name>Yu Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JiangSu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Changying Xing</last_name>
    </contact>
    <investigator>
      <last_name>Changying Xing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Xun</last_name>
    </contact>
    <investigator>
      <last_name>Yan Xun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyong Guo</last_name>
    </contact>
    <investigator>
      <last_name>Zhiyong Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Detian Li</last_name>
    </contact>
    <investigator>
      <last_name>Detian Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tonghua Central Hospital</name>
      <address>
        <city>Tonghua</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuping Zhao</last_name>
    </contact>
    <investigator>
      <last_name>Shuping Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fifth Hospital in Wuhan</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohui Wang</last_name>
    </contact>
    <investigator>
      <last_name>Xiaohui Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guohua Ding</last_name>
    </contact>
    <investigator>
      <last_name>Guohua Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Shui</last_name>
    </contact>
    <investigator>
      <last_name>Hua Shui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengmin Shao</last_name>
    </contact>
    <investigator>
      <last_name>Fengmin Shao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Zunyi Medical University</name>
      <address>
        <city>Zunyi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yibin Yang</last_name>
    </contact>
    <investigator>
      <last_name>Yibin Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Diseases</keyword>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Hyperphosphatemia</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Phosphorus Metabolism Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

